01 Expansion of Research in PGA Composites A significant trend shaping the global polyglycolic acid (PGA) market is the surge in research focused on PGA-based composites for tissue engineering and drug delivery. PGA's biodegradability, mechanical strength, and compatibility with biological tissues make it highly attractive for advanced biomedical applications. For example, a 2022 study published in the Journal of Biomedical Research detailed research from the National Institute of Technology Rourkela, where scientists developed chitosan–polygalacturonic acid (PgA) fibrous scaffolds using hydrothermal treatment. These scaffolds exhibited superior mechanical properties and porosity, facilitating improved cell adhesion and osteogenic differentiation in vitro, key indicators of suitability for bone tissue engineering. Such innovations highlight the expanding scope of PGA beyond conventional uses, reinforcing its role in next-generation regenerative medicine solutions.
May 2026 Kureha Corporation expanded its polyglycolic acid (PGA) production capabilities with advanced polymer technologies designed for medical sutures, oil & gas applications, and high-performance packaging materials.
March 2026 Corbion introduced new bio-based PGA-related polymer solutions as part of its sustainable materials portfolio, supporting demand for biodegradable and environmentally friendly alternatives.
October 2025 Huizhou Foryou Medical Devices expanded its PGA-based medical product portfolio with advanced absorbable surgical materials designed to improve wound closure performance and patient recovery.
June 2025 Mitsubishi Chemical Group strengthened its biodegradable polymer initiatives by advancing high-performance PGA materials for sustainable packaging and industrial applications.